High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes

Cancer

Volumn 118, Issue 11, 2012, Pages 2905-2914

  Choy, Edwin ^a,b   Hornicek, Francis ^b   MacConaill, Laura ^c   Harmon, David ^a   Tariq, Zeeshan ^d   Garraway, Levi ^c   Duan, Zhenfeng ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

Author keywords

alpha polypeptide; catalytic; genotyping; mutation; OncoMap; osteosarcoma; phosphoinositide 3 kinase

Indexed keywords

ALANINE; APC PROTEIN; ARGININE; ASPARAGINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CADHERIN; CADHERIN 1; CATENIN; CUBILIN; CYSTEINE; GENOMIC DNA; GLUTAMIC ACID; GLYCINE; HISTIDINE; ISOLEUCINE; K RAS PROTEIN; LYSINE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC ALPHA POLYPEPTIDE; PROLINE; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SERINE; THREONINE; TYROSINE; UNCLASSIFIED DRUG; UVOMORULIN; VALINE;

ADULT; AGED; ARTICLE; CABYR BINDING PROTEIN GENE; CANCER CELL CULTURE; CARCINOGENESIS; CELL FREE SYSTEM; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC CODE; GENETIC IDENTIFICATION; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE ABL1; ONCOGENE ABL2; ONCOGENE ADAMTSL3; ONCOGENE AKT1; ONCOGENE AKT2; ONCOGENE AKT3; ONCOGENE ALK; ONCOGENE AML1; ONCOGENE APC; ONCOGENE AR; ONCOGENE AXL; ONCOGENE BMX; ONCOGENE BRAF; ONCOGENE BRCA2; ONCOGENE BUB1B; ONCOGENE C MYC; ONCOGENE C14ORF155; ONCOGENE CDH1; ONCOGENE CDK4; ONCOGENE CDKN2A; ONCOGENE CEBPA; ONCOGENE CTNNB1; ONCOGENE CUBN; ONCOGENE DBL; ONCOGENE DBN1; ONCOGENE EGFR; ONCOGENE EPHA1; ONCOGENE EPHA3; ONCOGENE EPHB1; ONCOGENE EPHB6; ONCOGENE ERBB2; ONCOGENE ERBB4; ONCOGENE FBXW7; ONCOGENE FES; ONCOGENE FGFR1; ONCOGENE FGFR2; ONCOGENE FGFR3; ONCOGENE FLJ13479; ONCOGENE FLNB; ONCOGENE FLT3; ONCOGENE FSCB; ONCOGENE GATA1; ONCOGENE GNAS; ONCOGENE GUCYY1A2; ONCOGENE HRAS; ONCOGENE IGF1R; ONCOGENE JAK2; ONCOGENE JAK3; ONCOGENE K RAS; ONCOGENE KDR; ONCOGENE KIT; ONCOGENE LRP1B; ONCOGENE MADH4; ONCOGENE MAP2K4; ONCOGENE MET; ONCOGENE MINK1; ONCOGENE MLL3; ONCOGENE MOS; ONCOGENE MPL; ONCOGENE MSH2; ONCOGENE MSH6; ONCOGENE MST1R; ONCOGENE MYH1; ONCOGENE NF1; ONCOGENE NOTCH1; ONCOGENE NPM; ONCOGENE NPM1; ONCOGENE NTRK1; ONCOGENE NTRK2; ONCOGENE NTRK3; ONCOGENE P53; ONCOGENE PDGFRA; ONCOGENE PDGFRB; ONCOGENE PDPK1; ONCOGENE PI3K; ONCOGENE PIK3CA; ONCOGENE PKHD1; ONCOGENE PRKCB1; ONCOGENE PTEN; ONCOGENE PTPN11; ONCOGENE RAF1; ONCOGENE RAS; ONCOGENE RB1; ONCOGENE ROBO1; ONCOGENE ROBO2; ONCOGENE ROS1; ONCOGENE RUNX1; ONCOGENE SMAD2; ONCOGENE SMAD4; ONCOGENE SMARCB1; ONCOGENE SMO; ONCOGENE SPTAN1; ONCOGENE STK11; ONCOGENE SUFU; ONCOGENE TBX22; ONCOGENE TEC; ONCOGENE TFDP1; ONCOGENE TIAM1; ONCOGENE TIF1; ONCOGENE TP53; ONCOGENE TRIM33; ONCOGENE TSC1; ONCOGENE VHL; OSTEOSARCOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENOTYPING TECHNIQUES; HUMANS; MIDDLE AGED; MUTATION; ONCOGENES; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84861333261     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26617     Document Type: Article

References (51)

1. Ferguson WS, Goorin AM,. Current treatment of osteosarcoma. Cancer Invest. 2001; 19: 292-315.
2. Geller DS, Gorlick R,. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010; 8: 705-718.
3. Gorlick R,. Osteosarcoma: clinical practice and the expanding role of biology. J Musculoskelet Neuronal Interact. 2002; 2: 549-551.
4. Meyers PA, Gorlick R,. Osteosarcoma. Pediatr Clin North Am. 1997; 44: 973-989.
5. Mankin HJ,. Pathophysiology of Orthopaedic Diseases. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2006.
6. Chi SN, Conklin LS, Qin J, et al. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2004; 42: 46-51.
7. Davis AM, Bell RS, Goodwin PJ,. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994; 12: 423-431.
8. Goorin AM, Frei E 3rd, Abelson HT,. Adjuvant chemotherapy for osteosarcoma: a decade of experience. Surg Clin North Am. 1981; 61: 1379-1389.
9. Chou AJ, Gorlick R,. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006; 6: 1075-1085.
10. Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res. 1999; 5: 621-627.
11. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC,. Survival data for 648 patients with osteosarcoma treated at 1 institution. Clin Orthop Relat Res. 2004; 429: 286-291.
12. O'Day K, Gorlick R,. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther. 2009; 9: 511-523.
13. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
14. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500.
15. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472-480.
16. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001; 344: 1052-1056.
17. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010; 363: 1727-1733.
18. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
19. Chou AJ, Geller DS, Gorlick R,. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs. 2008; 10: 315-327.
20. Gorlick R,. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 2009; 152: 467-478.
21. Marina N, Gebhardt M, Teot L, Gorlick R,. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004; 9: 422-441.
22. Chugh R,. Experimental therapies and clinical trials in bone sarcoma. J Natl Compr Canc Netw. 2010; 8: 715-725.
23. Duan Z, Choy E, Harmon D, et al. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther. 2009; 8: 2122-2130.
24. Kolb EA, Kamara D, Zhang W, et al. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer. 2010; 55: 67-75.
25. Ulaner GA, Vu TH, Li T, et al. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet. 2003; 12: 535-549.
26. Do SI, Jung WW, Kim HS, Park YK,. The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. Int J Oncol. 2009; 34: 797-803.
27. Freeman SS, Allen SW, Ganti R, et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer. 2008; 113: 1453-1461.
28. Kersting C, Gebert C, Agelopoulos K, et al. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin Cancer Res. 2007; 13: 2998-3005.
29. Wen YH, Koeppen H, Garcia R, et al. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Hum Pathol. 2007; 38: 1184-1191.
30. Ryu K, Choy E, Yang C, et al. Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. J Orthop Res. 2010; 28: 971-978.
31. Ryu K, Susa M, Choy E, et al. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway [serial online]. BMC Cancer. 2010; 10: 187.
32. Duan Z, Ji D, Weinstein EJ, et al. Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. Cancer Lett. 2010; 293: 220-229.
33. Yamaguchi U, Honda K, Satow R, et al. Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci. 2009; 100: 2268-2274.
34. Seong YS, Kamijo K, Lee JS, et al. A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J Biol Chem. 2002; 277: 32282-32293.
35. Gazitt Y, Kolaparthi V, Moncada K, Thomas C, Freeman J,. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. Int J Oncol. 2009; 34: 551-561.
36. Paoloni MC, Mazcko C, Fox E, et al. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs [serial online]. PLoS One. 2010; 5: e11013.
37. Zhou Q, Deng Z, Zhu Y, Long H, Zhang S, Zhao J,. mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. Med Oncol. 2010; 27: 1239-1245.
38. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007; 450: 893-898.
39. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314: 268-274.
40. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007; 39: 347-351.
41. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples [serial online]. PLoS One. 2009; 4: e7887.
42. MacConaill LE, Garraway LA,. Clinical implications of the cancer genome. J Clin Oncol. 2010; 28: 5219-5228.
43. Duan Z, Weinstein EJ, Ji D, et al. Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. Mol Cancer Ther. 2008; 7: 2377-2385.
44. Cleary JM, Shapiro GI,. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr Oncol Rep. 2010; 12: 87-94.
45. Paez J, Sellers WR,. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res. 2003; 115: 145-167.
46. Man TK, Lu XY, Jaeweon K, et al. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma [serial online]. BMC Cancer. 2004; 4: 45.
47. Lau CC, Harris CP, Lu XY, et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer. 2004; 39: 11-21.
48. Ito M, Barys L, O'Reilly T, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res. 2011; 17: 416-426.
49. Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol. 1996; 14: 467-472.
50. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008; 26: 2046-2051.
51. Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010; 42: 715-721.